NMI-1182
NMI-1182 is a nitric oxide-releasing prodrug of Naproxen (HY-15030). NMI-1182 is an orally active COX-1 and COX-2 inhibitor. NMI-1182 inhibits constitutive COX-1-mediated and inducible COX-2-mediated prostaglandin synthesis. NMI-1182 induces nitric oxide donor release, activating soluble guanylate cyclase to synthesize cGMP, causing vasodilation. NMI-1182 can be used for research on inflammation and pain.
For research use only. We do not sell to patients.
- CAS No.: 646509-43-5
- Formula: C17H18N2O9
- Molecular Weight:394.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
|
COX-1 |
COX-2 |
In Vitro
NMI-1182 inhibits COX-1 and COX-2 in human whole blood[1].
NMI-1182 is a potent NO donor in LLC-PK1 cells, inducing cGMP at concentrations as low as 3 nM[1].
NMI-1182 inhibits COX-1 and COX-2 activity in human whole blood, with −log IC50 values of 4.71 and 5.05 for COX-1 and COX-2, respectively[2].
NMI-1182 (70 μM; 15 min) induces cGMP synthesis in human hepatocytes[1].
NMI-1182 (1 nM-10 µM) produces concentration-dependent vasodilation in isolated rat aorta[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
NMI-1182 (5 mg/kg; oral; single administration 1 h before Carrageenan injection) significantly reduced leukocyte infiltration and decreased PGE2 levels by 90% in Carrageenan-induced air pouch inflammation rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats (Male, 180-220 g, fasted)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose 1 h prior to Carrageenan
-
Result:Showed comparable inhibition of paw oedema of between 50 and 65% at 3 h post-insult.
-
Animal Model:Sprague-Dawley rats (Male, 180-220 g)[2]
-
Dosage:5 mg/kg
-
Administration:p.o.; single dose 1 h prior to Carrageenan
-
Result:Significantly reduced Carrageenan-induced leukocyte influx.
Significantly reduced PGE2 levels in the exudates by 90%.
Chemical Information
-
CAS No. 646509-43-5
-
Molecular Weight 394.33
-
Formula C17H18N2O9
-
SMILES
O=C(OC[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O)[C@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NMI-1182 Related Classifications
HY-189119 Related Classifications
Powered by Bioz
Keywords
- NMI-1182
- 646509-43-5
- NMI1182
- NMI 1182
- COX
- Guanylate Cyclase
- Cyclic GMP-AMP Synthase
- human hepatocytes
- carrageenan-induced air pouch inflammation
- cGMP
- carrageenan-induced paw oedema
- prostaglandin synthesis
- soluble guanylate cyclase
- COX-1
- COX-2
- human renal proximal tubule epithelial cells
- LLC-PK1 cells
- Inhibitor
- inhibitor
- inhibit